vs
Side-by-side financial comparison of DYNAVAX TECHNOLOGIES CORP (DVAX) and Ranpak Holdings Corp. (PACK). Click either name above to swap in a different company.
DYNAVAX TECHNOLOGIES CORP is the larger business by last-quarter revenue ($94.9M vs $93.7M, roughly 1.0× Ranpak Holdings Corp.). On growth, DYNAVAX TECHNOLOGIES CORP posted the faster year-over-year revenue change (17.7% vs 2.3%). Over the past eight quarters, DYNAVAX TECHNOLOGIES CORP's revenue compounded faster (30.6% CAGR vs 13.7%).
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
Ranpak Holdings Corp. manufactures machines and paper products used in protective paper-based packing for shipping goods and merchandise for e-commerce and industry, along with automation solutions. The company is based in Concord, Ohio, and has production facilities and offices in Reno, Nevada; Kansas City, Missouri; the Netherlands; Czech Republic; Shanghai and Singapore. The paper packaging material can be used for multiple applications like wrapping, cushioning, void fill and cold chain p...
DVAX vs PACK — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $94.9M | $93.7M |
| Net Profit | $26.9M | — |
| Gross Margin | — | 39.0% |
| Operating Margin | 22.4% | -1.0% |
| Net Margin | 28.4% | — |
| Revenue YoY | 17.7% | 2.3% |
| Net Profit YoY | 53.0% | — |
| EPS (diluted) | $0.21 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $93.7M | ||
| Q3 25 | $94.9M | $83.6M | ||
| Q2 25 | $95.4M | $77.8M | ||
| Q1 25 | $68.2M | $77.6M | ||
| Q4 24 | $72.0M | $91.6M | ||
| Q3 24 | $80.6M | $78.6M | ||
| Q2 24 | $73.8M | $72.8M | ||
| Q1 24 | $50.8M | $72.5M |
| Q4 25 | — | — | ||
| Q3 25 | $26.9M | $-10.4M | ||
| Q2 25 | $18.7M | $-7.5M | ||
| Q1 25 | $-96.1M | $-10.9M | ||
| Q4 24 | $7.0M | — | ||
| Q3 24 | $17.6M | $-8.1M | ||
| Q2 24 | $11.4M | $5.5M | ||
| Q1 24 | $-8.7M | $-8.1M |
| Q4 25 | — | 39.0% | ||
| Q3 25 | — | 41.1% | ||
| Q2 25 | — | 37.1% | ||
| Q1 25 | — | 39.8% | ||
| Q4 24 | — | 45.2% | ||
| Q3 24 | — | 43.8% | ||
| Q2 24 | — | 43.5% | ||
| Q1 24 | — | 44.6% |
| Q4 25 | — | -1.0% | ||
| Q3 25 | 22.4% | -6.8% | ||
| Q2 25 | 15.1% | -12.5% | ||
| Q1 25 | -34.7% | -10.3% | ||
| Q4 24 | -2.3% | 1.5% | ||
| Q3 24 | 12.5% | -5.3% | ||
| Q2 24 | 7.0% | -7.1% | ||
| Q1 24 | -35.0% | -6.6% |
| Q4 25 | — | — | ||
| Q3 25 | 28.4% | -12.4% | ||
| Q2 25 | 19.6% | -9.6% | ||
| Q1 25 | -141.0% | -14.0% | ||
| Q4 24 | 9.8% | — | ||
| Q3 24 | 21.8% | -10.3% | ||
| Q2 24 | 15.4% | 7.6% | ||
| Q1 24 | -17.2% | -11.2% |
| Q4 25 | — | $-0.11 | ||
| Q3 25 | $0.21 | $-0.12 | ||
| Q2 25 | $0.14 | $-0.09 | ||
| Q1 25 | $-0.77 | $-0.13 | ||
| Q4 24 | $0.07 | $-0.13 | ||
| Q3 24 | $0.12 | $-0.10 | ||
| Q2 24 | $0.08 | $0.07 | ||
| Q1 24 | $-0.07 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $160.2M | $63.0M |
| Total DebtLower is stronger | — | $401.9M |
| Stockholders' EquityBook value | $534.1M | $534.9M |
| Total Assets | $946.5M | $1.1B |
| Debt / EquityLower = less leverage | — | 0.75× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $63.0M | ||
| Q3 25 | $160.2M | $49.9M | ||
| Q2 25 | $99.1M | $49.2M | ||
| Q1 25 | $51.7M | $65.5M | ||
| Q4 24 | $95.9M | $76.1M | ||
| Q3 24 | $119.3M | $69.5M | ||
| Q2 24 | $112.5M | $65.1M | ||
| Q1 24 | $132.0M | $55.1M |
| Q4 25 | — | $401.9M | ||
| Q3 25 | — | $403.1M | ||
| Q2 25 | — | $403.1M | ||
| Q1 25 | — | $405.2M | ||
| Q4 24 | — | $406.4M | ||
| Q3 24 | — | $403.2M | ||
| Q2 24 | — | $396.1M | ||
| Q1 24 | — | $396.7M |
| Q4 25 | — | $534.9M | ||
| Q3 25 | $534.1M | $537.8M | ||
| Q2 25 | $494.2M | $539.0M | ||
| Q1 25 | $530.9M | $544.1M | ||
| Q4 24 | $596.8M | $548.1M | ||
| Q3 24 | $681.4M | $564.3M | ||
| Q2 24 | $642.8M | $566.2M | ||
| Q1 24 | $618.5M | $560.0M |
| Q4 25 | — | $1.1B | ||
| Q3 25 | $946.5M | $1.1B | ||
| Q2 25 | $918.4M | $1.1B | ||
| Q1 25 | $945.9M | $1.1B | ||
| Q4 24 | $986.3M | $1.1B | ||
| Q3 24 | $1.1B | $1.1B | ||
| Q2 24 | $1.0B | $1.1B | ||
| Q1 24 | $986.6M | $1.1B |
| Q4 25 | — | 0.75× | ||
| Q3 25 | — | 0.75× | ||
| Q2 25 | — | 0.75× | ||
| Q1 25 | — | 0.74× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.71× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.71× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $33.8M | $19.5M |
| Free Cash FlowOCF − Capex | $32.6M | — |
| FCF MarginFCF / Revenue | 34.4% | — |
| Capex IntensityCapex / Revenue | 1.3% | — |
| Cash ConversionOCF / Net Profit | 1.26× | — |
| TTM Free Cash FlowTrailing 4 quarters | $80.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $19.5M | ||
| Q3 25 | $33.8M | $8.5M | ||
| Q2 25 | $23.4M | $-3.6M | ||
| Q1 25 | $-19.6M | $-1.3M | ||
| Q4 24 | $53.0M | $6.5M | ||
| Q3 24 | $19.5M | $10.1M | ||
| Q2 24 | $10.7M | $19.6M | ||
| Q1 24 | $-16.7M | $5.2M |
| Q4 25 | — | — | ||
| Q3 25 | $32.6M | — | ||
| Q2 25 | $22.0M | — | ||
| Q1 25 | $-23.6M | — | ||
| Q4 24 | $49.5M | — | ||
| Q3 24 | $18.1M | — | ||
| Q2 24 | $9.9M | — | ||
| Q1 24 | $-17.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | 34.4% | — | ||
| Q2 25 | 23.0% | — | ||
| Q1 25 | -34.6% | — | ||
| Q4 24 | 68.8% | — | ||
| Q3 24 | 22.5% | — | ||
| Q2 24 | 13.5% | — | ||
| Q1 24 | -34.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 5.8% | — | ||
| Q4 24 | 4.8% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 1.1% | — | ||
| Q1 24 | 1.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.26× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.52× | — | ||
| Q3 24 | 1.11× | — | ||
| Q2 24 | 0.94× | 3.56× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
PACK
| Other | $47.9M | 51% |
| Europe And Asia Segment | $45.8M | 49% |
